-> Child Labor & Education
-> Grow Trees
-> Re- Think
-> Reduce your Trash
-> Save Energy Save Electricity
-> Save paper Save trees
-> Save water save life
-> Things one must know
We appreciate your feedback, and will have great regard for the same.
Browser not compatible.
VIVAN Life Sciences Pvt. Limited.
511, Lodha Supremus,
Rd.No.22, Wagle Industrial Estate,
Thane-W, Mumbai - 400604,
Ph. : +91(22) 2587 0080/81/82
Fax : +91(22) 2587 0084
Website : http://www.vivanls.com
e Mail : email@example.com
GlobalData expects IPF market to more than treble to $3.2bn by 2025 >
Research and consulting firm GlobalData expects that the idiopathic pulmonary fibrosis (IPF) market will increase to $3.2bn by 2025 from just more than $900m in 2015.............
Merck, a leading science and technology company, announced today that the company has entered into an agreement with HAPPYneuron, >
Boehringer Ingelheim increases access to the medication for the treatment of HIV/AIDS............
Jubilant Life Sciences has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for Rizatriptan Benzoate Orally Disintegrating Tablets, 5 mg and 10 mg, the generic version of Maxalt-MLT Orally Disintegrating, 5 mg and 10 mg Tablets (of Merck), which is indicated for the acute treatment of migraine in adults and in pediatric patients;
Boehringer Ingelheim is announcing an expansion of its Intellectual Property (IP) enforcement policy. The IP enforcement policy had already been amended in 2007 by an easy-to-use, non-assert declaration for Viramune® (nevirapine)............
Keytruda, developed by Schering Plough / Merck and Co, and Opdivo, developed by Ono / Bristol-Myers Squibb, are estimated to account for 50% of the global immuno-oncology market by 2024, estimates a report from GlobalData.........
GlaxoSmithKline (GSK) has agreed to acquire Bristol-Myers Squibb's (BMS) pipeline of research and development (R&D) HIV assetsfor about $1.5bn;
Teva wins approval for COPAXONE to prevent relapse of multiple sclerosis............
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Teva Pharmaceutical Industries' once-daily COPAXONE (glatiramer acetate injection) 20mg injection for the prevention of relapse of multiple sclerosis;
rs Squibb's HIV assets............
Bristol-Myers Squibb announced that the National Institute for Health and Care Excellence (NICE) has recommended Daklinza (daclatasvir) in England and Wales for the treatment of adult patients with chronic hepatitis C virus (HCV) infection;
Jubilant Life Sciences wins ANDA approval for Rizatriptan Benzoate OD Tablets............
FDA approves Merrimack’s metastatic pancreatic cancer drug............
The US Food and Drug Administration (FDA) has approved Merrimack Pharmaceuticals’ metastatic pancreatic cancer drug, Onivyde;
UK launches largest trial to assess whether aspirin can fight cancer............
The world's largest clinical trial to see whether taking a daily dose of aspirin can stop cancer from recurring has been launched in the UK;
Pfizer-Allergan megamerger report prompts speculation about fallout for CROs............
Reports Pfizer is considering buying Allergan to create a company worth $330bn have once again raised fears of disruption for contract research organisations (CRO), although there are reasons to think the deal would be less troublesome than earlier megamergers;
Hanson, Shimadzu combine technologies to create an automated testing system............
Hanson Research and Shimadzu have teamed up to combine their respective technologies into an automated online pharmaceutical testing system;
hVIVO invests in PrEP Biopharm............
hVIVO has made an investment in the UK-based start-up, PrEP Biopharm, to further develop new prophylactic treatment for respiratory infections;
Tara Immuno-Oncology acquires licenses to develop clinical stage p53MVA oncology vaccine............
Tara Immuno-Oncology has acquired licenses from City of Hope for the development of p53MVA (modified vaccinia ankara) and a Salmonella-based therapy targeting Indoleamine 2,3-Dioxygenase (shIDO-ST), both for multiple oncology indication;
p>FDA approves Gilead Sciences' Genvoya HIV drug............
The US Food and Drug Administration (FDA) has approved Gilead Sciences' Genvoya HIV drug to treat patients aged 12 and above;
LEO Pharma to buy Astellas Pharma's global dermatology portfolio............
LEO Pharma has agreed to acquire Astellas Pharma's global dermatology business for €675m;
Emerson, GE Healthcare partner to increase biopharma manufacturing efficiency............
Emerson Process Management has partnered with GE Healthcare’s Life Sciences business to increase productivity and improve efficiency in the production of biopharmaceuticals;
AstraZeneca agrees to sell US rights for Entocort drug to Perrigo............
AstraZeneca has agreed to sell the US rights for its gastrointestinal drug Entocort to Perrigo for $380m;
Acquired Sigma-Aldrich businesses part of Merck's Africa growth plan............
New acquisition Sigma Aldrich will play a part in African growth plans in addition to giving it a presence in the preclinical services sector says Merck;
Online Product Assistant
VIVAN Life Sciences is a Knowledge based and technology driven innovative Global Enterprise, offering higher end products in Pharmaceuticals and Life Sciences.
We provide break through collaboration for the niche pharmaceutical products, which enhance the capability and productivity performances of our customers and Business Associates around the world, In specific functions critical to their success.
Our Esteemed Clientele consists of, Global Pharmaceuticals and Life Sciences Companies, Pharmaceutical Generic companies, CROs (Contract Research Organizations), Clinical Research, Speciality Chemical Companies, Medical Research Organizations, world renowned Research Institutes and Universities.
We are instrumental in providing the higher-end products to our clientele around the world, and played an important role in the success of their Crucial projects.
there by improving and deriving exceptional value to the Projects critical to their success.
Please visit VIVAN BLOG:
Last but not the least, We welcome your participation. This certainly helps us to better the content sharing on VIVAN BLOG